Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC / OncoDaily

oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology

Christine M. Lovly։ Dr. Ross Camidge’s Incredible Presentation at the IASLC TTLC Meeting

17 days / oncodaily

Rishabh Jain: Antibiotics, Microbiome and Immunotherapy Outcomes in Lung Cancer

17 days / oncodaily

Dual Immunotherapy and the Microbiome Signal – Lung Cancer Europe

17 days / oncodaily

This Report Provides a Clear View of Where We Stand in Addressing Cancer – LUNGevity Foundation

18 days / oncodaily

Updated Oncogene-Addicted mNSCLC Living Guideline v1.3

18 days / esmo

Narjust Florez: Meaningful Connections at the 2026 Targeted Therapies of Lung Cancer Meeting

19 days / oncodaily

Ahmet Dirican: Real-World Data Discontinuation of Immunotherapy at 24 months in Metastatic NSCLC

19 days / oncodaily

Chinmay Jani Discusses Real-World Impact of Subcutaneous Amivantamab at TTLC 2026

19 days / oncodaily

Simon Heeke: Innovative Approaches for Lung Cancer Screening and Interception

19 days / oncodaily

Editors’ Picks, February 2026: FDA’s Accelerated Approval Pathway, Overcoming Resistance to KRAS Inhibition, and More

19 days / aacr / Cancer Research Catalyst Staff

When Promising Results Demand Rigorous Scrutiny: Lessons from the LungTIME-C01 Trial

19 days / oncodaily

Vandana Mahajan: 169th Lung Connect Meeting Showcases the Role of Clinical Trials

20 days / oncodaily

Yvonne Diaz: IASLC Programs Open Opportunities for Lung Cancer Advocates in Research

20 days / oncodaily

Eric Singhi: Innovative Approaches for Lung Cancer Screening and Interception

20 days / oncodaily

Rajat Thawani: Talking About NGR1 Fusions in NSCLC at TTLC26

20 days / oncodaily

Mamtha Balla: ITE Boards Pearls for Metastatic NSCLC

21 days / oncodaily

Giannis Mountzios: ESMO Advanced Course on Early-Stage NSCLC

21 days / oncodaily

Gavitt Woodard: Great Time at TTLCC26 With Yale Thoracic Group

21 days / oncodaily

Fawzi Abu Rous: Inspiration, Insights and Impact from TTLC 2026

22 days / oncodaily

Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC

23 days / oncodaily

Fawzi Abu Rous Kicks Off Season 2 of LungCancerRx LIVE at TTLC 2026

24 days / oncodaily

Fawzi Abu Rous: Integrating the Latest Evidence Into the Treatment of EGFR-mutated NSCLC

24 days / oncodaily

Study finds immune signature linked to treatment-resistant myasthenia gravis

24 days / medicalxpress

Monday, February 23, 2026, 2:22 am / permalink 19557 / 23 stories in 21 days

Related Stories

Related Tags

Healthcare

EPA proposes rollback on ethylene oxide sterilizer emissions (20 min)

Two deaths prompt probe of paid plasma donation clinics in Winnipeg (1 hr)

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (18 hrs)

more #healthcare

Pharmaceuticals

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (19 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (22 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (34 hrs)

more #pharmaceuticals

Biotech

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (19 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (22 hrs)

HORMAD1 emerges as a potential target in triple‑negative breast cancer (47 hrs)

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.